Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03801681
Other study ID # ARMY
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date November 1, 2018
Est. completion date December 31, 2020

Study information

Verified date January 2019
Source Medical University of Warsaw
Contact Krzysztof Ozieranski, MD
Phone 22 5991958
Email krzysztof.ozieranski@gmail.com
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

Myocarditis promotes the occurrence of serious cardiac arrhythmias and conduction disorders which may lead to sudden cardiac death, the need for catheter ablation of arrhythmia or implantation of a cardioverter-defibrillator or pacemaker. The aim of the study is to fill the evidence gap regarding the type and burden of arrhythmias in patients with myocarditis and their correlation with clinical parameters, biomarkers and additional tests. During a multi-center observational study, patients will be subjected to prolonged ECG monitoring. As a result, a risk scale will be created that can facilitate the identification of patients with an increased risk of arrhythmia and further specifying recommendations for therapeutic management.


Description:

Myocarditis is a serious social problem, usually affecting young or middle-aged people. Making of the diagnosis of myocarditis, due to the varied course of the disease, is a significant challenge, therefore clinical suspicion of myocarditis is based on symptoms and abnormalities in additional tests (ECG, echocardiography, magnetic resonance of the heart, biomarkers), which should be confirmed by cardiac biopsy. Despite the fact that in the majority of patients myocarditis occurs in a mild and uncomplicated manner, in some patients the inflammatory process progresses leading to dilated cardiomyopathy, end-stage heart failure and often to the need for heart transplantation. Myocarditis also promotes the occurrence of severe arrhythmias and conduction which may lead to sudden cardiac death (myocarditis is confirmed in autopsy even in 2-42% of cases), the need for percutaneous ablation of arrhythmia, cardioverter-defibrillator implantation or cardiac stimulator.

In order to better identify the causes and improve the diagnosis and treatment of myocarditis, new data are needed including biomarkers (including biochemical, genetic, immunohistochemical biomarkers) responsible for the process of necrosis, fibrosis, haemodynamic stress of myocardium in the course of myocarditis, as well as studies aimed at identifying pathogens that cause myocarditis and factors predisposing to the onset of myocarditis. In addition, there is no systematic information on the type and burden of arrhythmias and their variability over time. A significant deficiency of research in the field of the above biomarkers and the severity of arrhythmia in the course of myocarditis translates into the lack of clear recommendations on the myocarditis management from the scientific societies and often leads to wrong therapeutic decisions.

The aim of the study is to fill the evidence gap regarding the diagnostic and prognostic value of biomarkers, as well as the type and burden of arrhythmias in patients with myocarditis.

This will be a non-interventional, observational study. The study will include 100 adult patients with confirmed (based on clinical findings, in accordance with applicable guidelines) first myocarditis episode, who agree to participate in the study.

During the multicenter observational study will be collected basic demographic data, current diagnosis, current disease history and clinical presentation of symptoms, laboratory tests results and all other additional tests carried out during or after index hospitalization. During the index hospitalization peripheral venous blood (10 ml) will be collected to obtain serum for further diagnostic tests (i.e. biochemical, genetic). The obtained material will be stored frozen until analysis. The tested biomarkers will include those that have a confirmed role in the diagnosis of myocardial necrosis, in inflammatory processes and fibrosis of the myocardium, participate in the pathophysiology of arrhythmia and heart failure development, i.e. high sensitive troponin, N-terminal-pro Brain Natriuretic Peptide (NT-proBNP), Galectin-3, (Suppression of Tumorigenicity 2) ST2.

Additionally, in selected cases, when a biopsy of the heart is performed in the course of the independent diagnostic procedure, the heart muscle biopsies will be analyzed. In the collected material (both in blood and biopsy samples) immunohistochemistry, virology and genetic research will be performed for specific antibodies and genetic material of pathogens causing myocarditis (mainly viruses, i.e. parvovirus B19, coxsackie, adenovirus).

The immunogenetic predisposition, as well as gene profiling of people who have become ill with myocarditis will also be sought.

In addition, patients will undergo prolonged ECG Holter monitoring for up to 7 days from the moment of consenting to participate in the study. Registered ECG recordings will be evaluated after the completed follow-up period. Then, after 3-months form inclusion in the study, a control visit will be made assessing the clinical condition of patients, clinical examination, collection of blood samples, standard resting 12-lead ECG, and 7-day ECG-Holter monitoring. Other study endpoints will be assessed after 1-year observation. The next stage will be the analysis of clinical history, obtained results of ECG monitoring, biomarkers and additional tests.


Recruitment information / eligibility

Status Recruiting
Enrollment 100
Est. completion date December 31, 2020
Est. primary completion date December 31, 2020
Accepts healthy volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- clinically suspected myocarditis

- age = 18 years

- signed informed consent to participate in the study

Exclusion Criteria:

- previous history of heart failure

- already Implanted implantable cardioverter-defibrillator (ICD), cardiac resynchronization therapy (CRT) or pacemaker (PM)

- history of percutaneous ablation due to arrhythmias

- history of arrhythmias or conduction disorders

- active cancer

- advanced chronic kidney disease

- chronic inflammatory disease

- previous or current myocardial infarction

- current myocardial ischemia as the cause of arrhythmia

Study Design


Intervention

Diagnostic Test:
ECG holter monitoring
patients will be monitored using ECG-holter

Locations

Country Name City State
Poland 1st Chair and Department of Cardiology, Medical University of Warsaw Warsaw

Sponsors (1)

Lead Sponsor Collaborator
Medical University of Warsaw

Country where clinical trial is conducted

Poland, 

Outcome

Type Measure Description Time frame Safety issue
Primary Assessment of type and burden of arrhythmia using Holter-ECG monitoring in patients with myocarditis. During the Holter-ECG monitoring type and burden of arrhythmias or cardiac rhythm disorders will be assessed. 3 months
Primary Time to occurrence of new heart failure, heart failure hospitalizations or heart failure outpatient visits. it will be assessed on clinical interview during control visits 1 year
Primary Time to occurrence of cardiovascular hospitalization. it will be assessed on clinical interview during control visits 1 year
Primary Time to occurrence to left ventricular systolic dysfunction. left ventricular systolic dysfunction occurrence will be assessed using echocardiography during control visits. 1 year
Primary Time to occurrence to left ventricular diastolic dysfunction. left ventricular diastolic dysfunction occurrence will be assessed using echocardiography during control visits. 1 year
Secondary Correlation of serum biomarkers concentrations with cardiac remodeling 1 year
Secondary Correlation of serum biomarkers concentrations with inflammation 1 year
See also
  Status Clinical Trial Phase
Recruiting NCT05650307 - CV Imaging of Metabolic Interventions
Recruiting NCT05196659 - Collaborative Quality Improvement (C-QIP) Study N/A
Recruiting NCT05654272 - Development of CIRC Technologies
Active, not recruiting NCT05896904 - Clinical Comparison of Patients With Transthyretin Cardiac Amyloidosis and Patients With Heart Failure With Reduced Ejection Fraction N/A
Completed NCT05077293 - Building Electronic Tools To Enhance and Reinforce Cardiovascular Recommendations - Heart Failure
Recruiting NCT05631275 - The Role of Bioimpedance Analysis in Patients With Chronic Heart Failure and Systolic Ventricular Dysfunction
Enrolling by invitation NCT05564572 - Randomized Implementation of Routine Patient-Reported Health Status Assessment Among Heart Failure Patients in Stanford Cardiology N/A
Enrolling by invitation NCT05009706 - Self-care in Older Frail Persons With Heart Failure Intervention N/A
Recruiting NCT04177199 - What is the Workload Burden Associated With Using the Triage HF+ Care Pathway?
Terminated NCT03615469 - Building Strength Through Rehabilitation for Heart Failure Patients (BISTRO-STUDY) N/A
Recruiting NCT06340048 - Epicardial Injection of hiPSC-CMs to Treat Severe Chronic Ischemic Heart Failure Phase 1/Phase 2
Recruiting NCT05679713 - Next-generation, Integrative, and Personalized Risk Assessment to Prevent Recurrent Heart Failure Events: the ORACLE Study
Completed NCT04254328 - The Effectiveness of Nintendo Wii Fit and Inspiratory Muscle Training in Older Patients With Heart Failure N/A
Completed NCT03549169 - Decision Making for the Management the Symptoms in Adults of Heart Failure N/A
Recruiting NCT05572814 - Transform: Teaching, Technology, and Teams N/A
Enrolling by invitation NCT05538611 - Effect Evaluation of Chain Quality Control Management on Patients With Heart Failure
Recruiting NCT04262830 - Cancer Therapy Effects on the Heart
Completed NCT06026683 - Conduction System Stimulation to Avoid Left Ventricle Dysfunction N/A
Withdrawn NCT03091998 - Subcu Administration of CD-NP in Heart Failure Patients With Left Ventricular Assist Device Support Phase 1
Recruiting NCT05564689 - Absolute Coronary Flow in Patients With Heart Failure With Reduced Ejection Fraction and Left Bundle Branch Block With Cardiac Resynchronization Therapy